drugset / Trial / NCT05762640
Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
Phase 2
Recruiting
20 enrolled
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this project is to study the survival of patients until Haematopoietic Stem Cell Transplantation following the use of Ruxolitinib as first-line treatment associated to corticosteroids in primary HLH.
Timeline
- Start
- 2024-11-10
- Primary completion
- 2027-05
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 50 mg/m2 | — |
| Background | Methylprednisolone | Other / unclassified | 2 mg/kg | Intravenous |
| Background | Prednisolone | Other / unclassified | 2 mg/kg | Oral |